{"id":835204,"date":"2025-04-08T16:13:41","date_gmt":"2025-04-08T20:13:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/"},"modified":"2025-04-08T16:13:41","modified_gmt":"2025-04-08T20:13:41","slug":"neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/","title":{"rendered":"NeOnc Technologies Announces Near Completion\u00a0of Phase I Enrollment for NEO212 Brain Cancer Therapy"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CALABASAS, Calif., April  08, 2025  (GLOBE NEWSWIRE) &#8212; <strong>NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI)<\/strong>, a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that its Phase I clinical trial of NEO212, a development-stage bio-conjugated therapeutic for brain cancer, is nearing full enrollment. The final cohort (Cohort 5) is expected to complete the study\u2019s dosing protocol, marking a major milestone in the drug\u2019s development timeline.<\/p>\n<p align=\"left\">NEO212 is a proprietary conjugation of temozolomide (TMZ)\u2014the current standard-of-care chemotherapy for malignant gliomas\u2014and perillyl alcohol (POH), a naturally occurring compound with anti-cancer properties. While the use of TMZ alone has served as a frontline treatment for brain cancers for years, it suffers from key limitations such as rapid degradation in the bloodstream, bone marrow suppression due to toxic metabolites, and limited effectiveness in tumors with active MGMT DNA-repair enzyme expression. NEO212 is designed to address these concerns by creating a stable, orally bioavailable molecule that retains activity in both MGMT-positive and MGMT-negative gliomas.<\/p>\n<p align=\"left\">\u201cFor patients battling brain cancer and other CNS diseases, the ability to deliver more drug to the tumor site with far fewer systemic side effects, could fundamentally shift how we treat these conditions,\u201d said Amir Heshmatpour, Executive Chairman of NeOnc Technologies. \u201cOur clinical results to date underscore the therapeutic potential of NeOnc\u2019s delivery platform to redefine brain cancer treatment and open pathways for application across a broader range of CNS disorders.\u201d<\/p>\n<p align=\"left\">The NEO212 trial protocol includes five escalating cohorts (3 patients per cohort).<\/p>\n<p align=\"left\">\n        <strong>ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.<\/strong><br \/>\n        <br \/>NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company\u2019s NEO\u2122 drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc\u2019s NEO100\u2122 and NEO212\u2122 therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.<\/p>\n<p align=\"left\">For more about NeOnc and its pioneering technology, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PK51YTIC0ZS72qcvIYw3pNjIoNuxK9ZbQK_-gRLvr21rj578XjXf-uA_0cv7AAzMF4nbuVwGdkrxTY5nkGmPog==\" rel=\"nofollow\" target=\"_blank\"><u>neonctech.com<\/u><\/a>.<\/p>\n<p align=\"left\">\n        <strong>Important Cautions Regarding Forward Looking Statements <\/strong><br \/>\n        <br \/>All statements other than statements of historical facts included in this press release are &#8220;forward-looking statements&#8221; (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as &#8220;projected,&#8221; &#8220;expect,&#8221; &#8220;possibility&#8221; and &#8220;anticipate,&#8221; or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law.<\/p>\n<p align=\"left\">\u201cNEO100\u201d is a registered trademark of NeOnc Technologies Holdings, Inc.<\/p>\n<p align=\"left\">\n        <strong>Company Contact: <\/strong><br \/>\n        <br \/>Patrick Walters<br \/>Chief Operations Officer<br \/>NeOnc Technologies Holdings, Inc. <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XPyU7YcvZJpFOuOP3VjKzxRPSZhRZKS4zFhBQW8eq4syeMyYBUcxnvHIFJRh8lUoJpxoNJjjeBzV9SXJXz2wqQ==\" rel=\"nofollow\" target=\"_blank\">info@neonc.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Investor Relations: <\/strong><br \/>\n        <br \/>Roger Pondel \/ Laurie Berman<br \/>PondelWilkinson Inc.<br \/>(310) 279-5980<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oSskrBN-cFbu14WGvaLmb6k-yYNNDzWGImlGlJ7m_fCoaVlJWFFfeY4xjgCgqReYJI8w71Svy7EEh7RWIr4n0W2QQ-ORuRsGqeRxJjW0BRA=\" rel=\"nofollow\" target=\"_blank\">rpondel@pondel.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NpT4X01B1a_vnQjDZn4ZOUwVtN5ufaiqKzM2dWI08L9CPUjT2aNTOdYvovgLzqrDlIG5NfiVO0kNSNM0S_kyWKPfApj9N5nYiNYYEnXwdRk=\" rel=\"nofollow\" target=\"_blank\">lberman@pondel.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxODk1NyM2ODU2ODI0IzIyNTY4Mzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjJiNTdkNzEtYjc5OS00NWI1LWEwYzktNDlkNDRmZjg5MjBjLTEyNjgzODctMjAyNS0wNC0wOC1lbg==\/tiny\/NeOnc-Technologies-Holdings-In.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CALABASAS, Calif., April 08, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that its Phase I clinical trial of NEO212, a development-stage bio-conjugated therapeutic for brain cancer, is nearing full enrollment. The final cohort (Cohort 5) is expected to complete the study\u2019s dosing protocol, marking a major milestone in the drug\u2019s development timeline. NEO212 is a proprietary conjugation of temozolomide (TMZ)\u2014the current standard-of-care chemotherapy for malignant gliomas\u2014and perillyl alcohol (POH), a naturally occurring compound with anti-cancer properties. While the use of TMZ alone has served as a frontline treatment for brain cancers for years, it suffers from key limitations such &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NeOnc Technologies Announces Near Completion\u00a0of Phase I Enrollment for NEO212 Brain Cancer Therapy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-835204","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NeOnc Technologies Announces Near Completion\u00a0of Phase I Enrollment for NEO212 Brain Cancer Therapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeOnc Technologies Announces Near Completion\u00a0of Phase I Enrollment for NEO212 Brain Cancer Therapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CALABASAS, Calif., April 08, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that its Phase I clinical trial of NEO212, a development-stage bio-conjugated therapeutic for brain cancer, is nearing full enrollment. The final cohort (Cohort 5) is expected to complete the study\u2019s dosing protocol, marking a major milestone in the drug\u2019s development timeline. NEO212 is a proprietary conjugation of temozolomide (TMZ)\u2014the current standard-of-care chemotherapy for malignant gliomas\u2014and perillyl alcohol (POH), a naturally occurring compound with anti-cancer properties. While the use of TMZ alone has served as a frontline treatment for brain cancers for years, it suffers from key limitations such &hellip; Continue reading &quot;NeOnc Technologies Announces Near Completion\u00a0of Phase I Enrollment for NEO212 Brain Cancer Therapy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-08T20:13:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxODk1NyM2ODU2ODI0IzIyNTY4Mzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeOnc Technologies Announces Near Completion\u00a0of Phase I Enrollment for NEO212 Brain Cancer Therapy\",\"datePublished\":\"2025-04-08T20:13:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\\\/\"},\"wordCount\":671,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxODk1NyM2ODU2ODI0IzIyNTY4Mzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\\\/\",\"name\":\"NeOnc Technologies Announces Near Completion\u00a0of Phase I Enrollment for NEO212 Brain Cancer Therapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxODk1NyM2ODU2ODI0IzIyNTY4Mzg=\",\"datePublished\":\"2025-04-08T20:13:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxODk1NyM2ODU2ODI0IzIyNTY4Mzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxODk1NyM2ODU2ODI0IzIyNTY4Mzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeOnc Technologies Announces Near Completion\u00a0of Phase I Enrollment for NEO212 Brain Cancer Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeOnc Technologies Announces Near Completion\u00a0of Phase I Enrollment for NEO212 Brain Cancer Therapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/","og_locale":"en_US","og_type":"article","og_title":"NeOnc Technologies Announces Near Completion\u00a0of Phase I Enrollment for NEO212 Brain Cancer Therapy - Market Newsdesk","og_description":"CALABASAS, Calif., April 08, 2025 (GLOBE NEWSWIRE) &#8212; NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that its Phase I clinical trial of NEO212, a development-stage bio-conjugated therapeutic for brain cancer, is nearing full enrollment. The final cohort (Cohort 5) is expected to complete the study\u2019s dosing protocol, marking a major milestone in the drug\u2019s development timeline. NEO212 is a proprietary conjugation of temozolomide (TMZ)\u2014the current standard-of-care chemotherapy for malignant gliomas\u2014and perillyl alcohol (POH), a naturally occurring compound with anti-cancer properties. While the use of TMZ alone has served as a frontline treatment for brain cancers for years, it suffers from key limitations such &hellip; Continue reading \"NeOnc Technologies Announces Near Completion\u00a0of Phase I Enrollment for NEO212 Brain Cancer Therapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-08T20:13:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxODk1NyM2ODU2ODI0IzIyNTY4Mzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeOnc Technologies Announces Near Completion\u00a0of Phase I Enrollment for NEO212 Brain Cancer Therapy","datePublished":"2025-04-08T20:13:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/"},"wordCount":671,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxODk1NyM2ODU2ODI0IzIyNTY4Mzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/","name":"NeOnc Technologies Announces Near Completion\u00a0of Phase I Enrollment for NEO212 Brain Cancer Therapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxODk1NyM2ODU2ODI0IzIyNTY4Mzg=","datePublished":"2025-04-08T20:13:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxODk1NyM2ODU2ODI0IzIyNTY4Mzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxODk1NyM2ODU2ODI0IzIyNTY4Mzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neonc-technologies-announces-near-completion-of-phase-i-enrollment-for-neo212-brain-cancer-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeOnc Technologies Announces Near Completion\u00a0of Phase I Enrollment for NEO212 Brain Cancer Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/835204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=835204"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/835204\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=835204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=835204"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=835204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}